SCHEMBL2923636

SCHEMBL2923636

CC(C)(C)OC(=O)c1cc(OCCCCCCCCCC(=O)NCCCC(=O)O)cc(C(=O)OC(C)(C)C)c1

nearest known ligand 0.50

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 17/20 0.50
CNR2 P34972 16/20 0.50
MEN1 O00255 1/20 0.42
HPGD P15428 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2925424 0.89 PLA2G2A (0.47) CNR1CNR2
SCHEMBL2925326 0.82 CNR1 (0.42) CNR1CNR2HPGD
SCHEMBL2927304 0.81 CNR2 (0.39) CNR1CNR2KMT2A
SCHEMBL2921102 0.79 PDE3B (0.41) CNR1CNR2
SCHEMBL1744284 0.78 LMNA (0.54)
SCHEMBL2182906 0.77 KMT2A (0.51) KMT2A
SCHEMBL2179684 0.77 KMT2A (0.51) KMT2A
SCHEMBL2182231 0.77 KMT2A (0.51) KMT2A
SCHEMBL13863177 0.77 PLA2G2A (0.52) CNR1CNR2MEN1HPGDKMT2A
SCHEMBL22097373 0.77 ITGB3 (0.43) CNR1CNR2MEN1HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1735358-B1 A PROCESS FOR THE PREPARATION OF VINYLAROMATIC (CO)POLYMERS GRAFTED ON AN ELASTOMER IN A CONTROLLED WAY VERSALIS SPA (IT) 2018-10-24 EP disclosed
US-8722620-B2 Insulin derivatives NOVO NORDISK A/S (DK) 2014-05-13 US disclosed
EP-2256129-A1 Insulin derivatives NOVO NORDISK A/S (DK) 2010-12-01 EP disclosed
EP-1991576-B1 INSULIN DERIVATIVES NOVO NORDISK AS (DK) 2010-09-29 EP disclosed
EP-1914283-B1 Photo-catalytic coating for metal materials GLOBAL ENGINEERING S R L (IT) 2010-09-29 EP disclosed
US-20090137454-A1 Insulin Derivatives NOVO NORDISK A/S (DK) 2009-05-28 US disclosed
EP-1991576-A1 INSULIN DERIVATIVES Novo Nordisk A/S (DK) 2008-11-19 EP disclosed
EP-1914283-A1 Photo-catalytic coating for metal materials Global Engineering and Trade S.p.A. (IT) 2008-04-23 EP disclosed
US-20070213469-A1 A process for the preparation of vicylaromatiic (co) polymers grafted on an elastomer in a cotrolled way POLIMERI EUROPA S.P.A. (IT) 2007-09-13 US disclosed
WO-2007096431-A1 INSULIN DERIVATIVES NOVO NORDISK A/S (DK) 2007-08-30 WO disclosed
EP-1735358-A1 A PROCESS FOR THE PREPARATION OF VINYLAROMATIC (CO)POLYMERS GRAFTED ON AN ELASTOMER IN A CONTROLLED WAY Polimeri Europa S.p.A. (IT) 2006-12-27 EP disclosed
WO-2005100425-A1 A PROCESS FOR THE PREPARATION OF VINYLAROMATIC (CO)POLYMERS GRAFTED ON AN ELASTOMER IN A CONTROLLED WAY POLIMERI EUROPA S.P.A. (IT) 2005-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137454-A1 Insulin Derivatives IAPP, INSR, GPR119 CNR1 3956/4885CNR2 4031/4885MEN1 626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.